Search

John J Koleng

from Santa Fe, TX
Get Report
Also known as:
John J Martinez, Koheng John
Phone and address:
4202 Chisholm Trl, Santa Fe, TX 77510
(409) 925-5681
Connected to:
Michael D Kolenic, 48Lauren P Kolenik, 41Robert J Kolenkow, 91Besim Kolenovic, 42Faik F Kolenovic, 59Renzo Kolenovic, 49Richard T Kolensky, 60Olukayode D Koleosho, 49Victor Koler, 72Judy F Koles, 72

John Koleng Phones & Addresses

  • 4202 Chisholm Trl, Santa Fe, TX 77510 (409) 925-5681
  • 11113 Alison Park Trl, Austin, TX 78750 (512) 401-0280
  • 3002 Boxdale Dr, Austin, TX 78757 (512) 452-4345
  • 4901 Holloway Rd, Alvin, TX 77511 (281) 925-5681 (409) 925-5681
  • College Station, TX

Work

Company: Product demos Jan 2009 Position: Advantage sales and marketing

Education

School / High School: Galveston Community College- Galveston, TX 1970 Specialities: Business Management

Public records

Vehicle Records

John Koleng

View page
Address:
11113 Alison Park Trl, Austin, TX 78750
Phone:
(512) 401-0280
VIN:
1ZVHT85H875335329
Make:
FORD
Model:
MUSTANG
Year:
2007

Resumes

Resumes

John Koleng Photo 1

Partner

View page
Location:
Austin, TX
Industry:
Pharmaceuticals
Work:
Regulatory Compliance Initiatives 2008 - 2017
Principal
Advanced Nutrition Sciences Jun 2012 - Mar 2015
Member
Dry Pharma, Llc Jan 2009 - May 2010
Pharmaceutical Sciences
The University of Texas at Austin Jan 2009 - May 2010
Adjunct Assistant Professor
Alphavektor, Llc Jan 2009 - May 2010
Partner
Education:
The University of Texas at Austin 1995 - 2002
Doctorates, Doctor of Philosophy The University of Texas at Austin 1989 - 1994
Bachelors, Bachelor of Science, Pharmacy
Skills:
Drug Delivery
Gmp
Drug Development
Pharmaceutical Industry
Fda
Pharmaceutics
Product Development
Validation
Technology Transfer
Commercialization
Glp
Biotechnology
Clinical Trials
Lifesciences
Leadership
Medical Devices
Capa
Quality System
Regulatory Affairs
Drug Discovery
Formulation
Biopharmaceuticals
Intellectual Property
Hplc
Packaging
R&D
Chemistry
Analytical Chemistry
Clinical Development
Cro
Gcp
Clinical Research
Manufacturing
Sop
Immunology
Uv/Vis
Biochemistry
Lc Ms
Oncology
Patents
V&V
Pharmacokinetics
Ind
Pharmaceutical Research
Regulatory Submissions
Protein Chemistry
Pharmacology
Chromatography
Organic Chemistry
Vaccines
John Koleng Photo 2

John Koleng Santa Fe, TX

View page
Work:
Product Demos

Jan 2009 to 2000
Advantage Sales and Marketing
AT&T Telecommunications Company
Texas City, TX
Feb 2007 to Jan 2009
Installation and Repair
Washington, DC
Jul 1968 to May 2007
Customer Service Technician
US Army

Jul 1966 to Jul 1968
Education:
Galveston Community College
Galveston, TX
1970 to 1974
Business Management
Ball High School
Galveston, TX
May 1966
John Koleng Photo 3

John Koleng

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
John Koleng
Vice-President
Communications Workers of America
Labor Organization
PO Box 292, Texas City, TX 77592
623 5 Ave N, Texas City, TX 77590
(409) 948-1133
John Koleng
President, Secretary
AXXIS INNOVATIONS, INC
Nonclassifiable Establishments
11113 Alison Park Trl, Austin, TX 78750
11113 Alison Parke Trl, Austin, TX 78750
John Koleng
Manager
VIA THERAPEUTICS, LLC
Commercial Physical Research Mfg Pharmaceutical Preparations
11113 Alison Park Trl, Austin, TX 78750
11113 Alison Parke Trl, Austin, TX 78750
John Koleng
AlphaVektor, LLC
Pharmaceuticals · Business Consulting Services
Austin, TX 78750
11113 Alison Park Trl, Austin, TX 78750
11113 Alison Parke Trl, Austin, TX 78750
John Koleng
Director
SF TRAILS HOMEOWNERS ASSOCIATION
Civic/Social Association
6710 Stewart Rd STE 300, Galveston, TX 77551
PO Box 815, Santa Fe, TX 77510
John Koleng
DRY PHARMA, LLC
Mfg Pharmaceutical Preparations
11113 Alison Park Trl, Austin, TX 78750
11113 Alison Parke Trl, Austin, TX 78750

Publications

Us Patents

Stabilized Compositions Containing Alkaline Labile Drugs

View page
US Patent:
8173152, May 8, 2012
Filed:
Mar 22, 2007
Appl. No.:
12/294367
Inventors:
Michael W. Crowley - Austin TX, US
Justin M. Keen - Austin TX, US
John J. Koleng - Austin TX, US
Feng Zhang - Austin TX, US
Assignee:
Auxilium US Holdings, LLC - Wilmington DE
International Classification:
A61F 13/02
US Classification:
424434
Abstract:
A stabilized bioadhesive composition containing an alkaline labile drug and a method for its preparation are provided. In one aspect, the composition is a hot-melt extruded (HME) composition comprising a preformed excipient mixture comprising an acidic component and an alkaline thermoplastic matrix-forming material, e. g. polymer. The excipient mixture is formed before blending with an alkaline labile drug. The blend is then hot-melt extruded to form the HME composition. By so doing, the acidic component is able to neutralize or render moderately acidic the excipient mixture. This particular process has been shown to substantially reduce the degradation of an alkaline labile drug during hot-melt extrusion. The excipient mixture softens or melts during hot-melt extrusion. It can dissolve or not dissolve drug-containing particles during extrusion.

Scf Extract Containing Cardiac Glycoside

View page
US Patent:
8394434, Mar 12, 2013
Filed:
Mar 12, 2012
Appl. No.:
13/417686
Inventors:
Otis Crandell Addington - San Antonio TX, US
Feng Zhang - Burlingame CA, US
John J. Koleng - Austin TX, US
Assignee:
Phoenix Biotechnology, Inc. - San Antonio TX
International Classification:
A61K 36/13
A61K 36/00
US Classification:
424770, 424725
Abstract:
A supercritical fluid (SCF) extract of a cardiac glycoside-containing plant mass is provided. The extract can be included in a pharmaceutical composition containing an extract-solubilizing amount of solubilizer. Oleandrin is included within the extract when a cardiac glycoside-containing plant, such as , is extracted by SCF extraction. The extract can also contain one or more other SCF extractable pharmacologically active agents. The composition can be used to treat a wide range of disorders that are therapeutically responsive to a cardiac glycoside.

Process For The Preparation Of A Hot-Melt Extruded Laminate

View page
US Patent:
8465759, Jun 18, 2013
Filed:
Mar 22, 2007
Appl. No.:
12/294372
Inventors:
Michael M. Crowley - Austin TX, US
Justin M. Keen - Austin TX, US
John J. Koleng - Austin TX, US
Feng Zhang - Austin TX, US
Assignee:
Auxilium US Holdings, LLC - Wilmington DE
International Classification:
A61F 13/00
A61K 47/00
A61L 15/00
B29C 47/06
B32B 37/00
US Classification:
424424, 264148, 264153, 2641731, 26417312, 26417315, 26417316, 264211, 424425, 424426, 424427, 424428, 424430, 424434, 424435, 424436, 424437, 424439, 424443, 424445, 424447, 424448, 424449, 514953, 514954, 514956
Abstract:
A process for the preparation of a bioadhesive laminate comprising a hot-melt extruded reservoir layer and a hot-melt extruded backing layer is provided. The reservoir layer comprises a thermoplastic bioadhesive composition containing an active agent. An active agent-containing thermoplastic bioadhesive hydrophilic composition is hot-melt coextruded with a hydrophobic composition to form at least a bi-layered laminate. The hydrophilic composition and the hydrophobic composition have at least one polymer in common. In addition, the melt flow index of the hydrophobic composition is within 50% of the melt flow index of the hydrophilic composition. As a result, the laminate has a uniform transverse cross-section and/or a uniform longitudinal cross-section throughout a major of the length of the laminate. Moreover, when the laminate is divided into unit doses of approximately the same size, they have a high degree of content uniformity with respect to the active agent(s) present therein.

Methods And Compositions For Treating Pain Of The Mucous Membrane

View page
US Patent:
20020013331, Jan 31, 2002
Filed:
Jun 25, 2001
Appl. No.:
09/888466
Inventors:
Robert Williams - Austin TX, US
Feng Zhang - Austin TX, US
John Koleng - Austin TX, US
Gavril Pasternak - New York NY, US
Yuri Kolesnikov - Tenafly NJ, US
International Classification:
A61K031/485
A61K009/14
US Classification:
514/282000, 424/486000
Abstract:
Compositions useful for long-lasting pain relief from mucosal damage, such as mucosal inflamation, abrasions, ulcerations, lesions, trauma and incisions, without significant systemic absorption. The compositions of the invention are particularly suitable for application to the mucous membrane of the nasal cavity and buccal cavity. To relieve pain, the compositions or the invention are topically applied directly to the affected area.

Methods And Compositions For Treating Pain Of The Mucous Membrane

View page
US Patent:
20020192288, Dec 19, 2002
Filed:
Jun 17, 2002
Appl. No.:
10/172455
Inventors:
Robert Williams - Austin TX, US
Feng Zhang - Austin TX, US
John Koleng - Austin TX, US
Gavril Pasternak - New York NY, US
Yuri Kolesnikov - Tenafly NJ, US
International Classification:
A61K009/14
A61K031/485
US Classification:
424/486000, 514/282000
Abstract:
Compositions useful for long-lasting pain relief from mucosal damage, such as mucosal inflamation, abrasions, ulcerations, lesions, trauma and incisions, without significant systemic absorption. The compositions of the invention are particularly suitable for application to the mucous membrane of the nasal cavity and buccal cavity. To relieve pain, the compositions or the invention are topically applied directly to the affected area.

Methods And Compositions For Treating Pain Of The Mucous Membrane

View page
US Patent:
20030124190, Jul 3, 2003
Filed:
Jan 21, 2003
Appl. No.:
10/347385
Inventors:
Robert Williams - Austin TX, US
Feng Zhang - Austin TX, US
John Koleng - Austin TX, US
Gavril Pasternak - New York NY, US
Yuri Kolesnikov - Tenafly NJ, US
Assignee:
EpiCept, Inc.
International Classification:
A61K031/485
A61K009/14
US Classification:
424/486000, 514/282000
Abstract:
Compositions useful for long-lasting pain relief from mucosal damage, such as mucosal inflamation, abrasions, ulcerations, lesions, trauma and incisions, without significant systemic absorption. The compositions of the invention are particularly suitable for application to the mucous membrane of the nasal cavity and buccal cavity. To relieve pain, the compositions or the invention are topically applied directly to the affected area.

Compressed Composition Comprising Magnesium Salt

View page
US Patent:
20050220865, Oct 6, 2005
Filed:
Apr 2, 2004
Appl. No.:
10/816771
Inventors:
John Koleng - Austin TX, US
Michael Crowley - Austin TX, US
International Classification:
A61K009/48
A61K009/20
A61K033/08
US Classification:
424451000, 424464000, 424692000
Abstract:
An oral solid compress composition comprising a magnesium salt is provided. The composition provides a rapid dissolution of the magnesium salt, wherein not less than 75% of the magnesium salt dissolves within 45 minutes after placement in hydrochloric acid (0.1 N, 900 mL) as per USP Method . In a particular embodiment, the magnesium salt is an inorganic salt such as MgO, Mg(OH), MgCl, and others. The composition can be prepared by dry granulation, direct compression or another suitable process. The composition provides a substantially stable dissolution profile for the magnesium salt so that the dissolution profile changes only minimally even after an extended period of storage under pharmaceutically acceptable conditions when packaged in a sealed container-enclosure system. The solid composition may also exclude a cellulose-based composition. The compressed composition can be prepared and stored under anhydrous conditions.

Extended Release Formulations Of Poorly Soluble Antibiotics

View page
US Patent:
20060193908, Aug 31, 2006
Filed:
Nov 4, 2005
Appl. No.:
11/267943
Inventors:
Beth Burnside - Bethesda MD, US
Colin Rowlings - Potomac IN, US
Sandra Wassink - Frederick MD, US
Donald Treacy - Woodbine MD, US
John Koleng - Austin TX, US
International Classification:
A61K 31/7048
A61K 9/20
US Classification:
424464000, 514029000
Abstract:
An extended release pharmaceutical compressed composition and dosage form comprising poorly water soluble macrolide antibiotic, surfactant and non-lipophilic, non-polymeric excipient is disclosed. The composition releases the macrolide antibiotic over an extended period of time, generally at least over 12 hours, even in the absence of a release rate-retarding polymer, release rate-retarding coating or release rate-retarding lipophilic excipient. The composition is suitable for once daily or twice daily oral administration for the treatment of many different types of bacterial infections. One embodiment of the compressed composition includes a drug-containing granular composition and a binding composition, wherein the two are mixed together and then compressed into a tablet or pill. The surfactant is in admixture with or coated onto the macrolide antibiotic, and it can be included in the granular composition and/or the binding composition. The non-polymeric, non-lipophilic excipient is included in the granular composition and/or the binding composition.
Control profile
John J Koleng from Santa Fe, TX Get Report